Personal Injury Lawyer Blog Providing
Info in Miami & Nationwide

"Colson Hicks Eidson is recognized as one of the top litigation firms in the country, handling local, national and international litigation for a wide range of clients." - Chambers USA

Pharmaceutical Litigation: Elmiron, Allergan, and Zantac Updates

December 14, 2021
Colson Hicks Eidson

Thousands of people are severely injured or killed each year by prescription and over-the-counter medications that they thought were safe. Prescription and over-the-counter drug adverse effects are one of the main causes of death in the United States.

There are currently ongoing lawsuits, pending settlements, and trials happening around common drugs across the United States. Three common drugs that are currently a hot issue for Miami pharmaceutical litigation attorneys are Elmiron, Allergan, and Zantac. If you have experienced any adverse issues with these drugs, contact Colson Hicks Eidson immediately. Our experienced attorneys can help you choose the best course of action for your claim.

Elmiron Update

Elmiron lawsuits are civil cases filed by people who took Elmiron and later suffered maculopathy or other major eyesight disorders. Janssen Pharmaceuticals allegedly knew about the potential of eye injury but failed to sufficiently notify the public, according to Elmiron lawsuits.

There are currently 622 Elmiron class-action lawsuits that have been filed, up from 580 in October. Lawyers are taking lawsuits from persons who used Elmiron for at least two years and developed visual difficulties, particularly if they took it from 2018 to the present.

These lawsuits could possibly head to trial in early 2023.

Allergan Update

Teva Pharmaceutical Industries Ltd. is the lone defendant remaining in a public-nuisance trial that is finishing up after six months of testimony. Allergan Plc agreed to pay $200 million to resolve a New York lawsuit over the marketing of highly addictive opioid medications.

According to a Bloomberg law article, Allergan, which was acquired by competitor drugmaker AbbVie Inc. last year, would pay the money by 2022, with the majority of it going to assist rebuild drug-treatment and social-service budgets devastated by the opioid epidemic. Allergan had previously pledged to stop producing painkillers.

Zantac Update

A Zantac lawsuit is a legal claim filed by people who developed cancer after taking Zantac and ranitidine tainted with NDMA. Zantac lawsuits seek compensation from the drug’s producers for cancers of the stomach, bladder, and other organs linked to NDMA, a suspected human carcinogen.

The first trial in the class action suit against Zantac is set for October 10,2022 in California. While the trial in California is the first to be scheduled, trials in the MDL in Florida, as well as a variety of other cases in Illinois, Minnesota, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Texas, and Washington, may be set before the Alameda, CA trial starts.

Contact a Pharmaceutical Litigation Attorney Today

If you have suffered any side effects or lost a loved one as a result of taking Elmiron, Allergan, or Zantac, the first step in preserving your rights is to contact a pharmaceutical litigation attorney. We, at Colson Hicks Eidson, are here to answer your questions and help you figure out what you need to do next in your quest for justice.

If you believe you have a case against any of these drug companies or should be a part of the class action lawsuits, contact our Miami pharmaceutical litigation attorneys at Colson Hicks Eidson today. We can be reached by phone at 305-476-7400 or by contacting us online.

    ×